LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Search

Lantheus Holdings Inc

Suletud

SektorTervishoid

96.06 3.4

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

92.01

Max

96.32

Põhinäitajad

By Trading Economics

Sissetulek

64M

118M

Müük

-29M

377M

P/E

Sektori keskmine

22.127

49.701

Aktsiakasum

1.46

Kasumimarginaal

31.383

Töötajad

1,193

EBITDA

-17M

81M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+11.15% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2026

Turustatistika

By TradingEconomics

Turukapital

321M

6B

Eelmine avamishind

92.66

Eelmine sulgemishind

96.06

Uudiste sentiment

By Acuity

47%

53%

150 / 345 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. mai 2026, 23:31 UTC

Kuumad aktsiad

Stocks to Watch: Intuit, Applied Digital, Osisko, Banzai

20. mai 2026, 22:52 UTC

Suurimad hinnamuutused turgudel

Osisko Shares Fall on Planned Convertible Notes Offering

20. mai 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 23:47 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

20. mai 2026, 23:44 UTC

Tulu

Musk Is In Total Control of SpaceX. The IPO Filing Has Finally Come. -- Barrons.com

20. mai 2026, 23:35 UTC

Market Talk

Gold Edges Lower Amid Slightly Higher U.S. Treasury Yields -- Market Talk

20. mai 2026, 23:30 UTC

Market Talk

Goodman Well-Placed for Earnings Guidance Upgrade -- Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 23:17 UTC

Market Talk

Ryman Healthcare Bull Focusing on Three Areas in FY26 Result -- Market Talk

20. mai 2026, 23:15 UTC

Market Talk

Mainfreight's FY26 Profit Fall May Mask Improving Performance -- Market Talk

20. mai 2026, 23:14 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 4th Update

20. mai 2026, 23:02 UTC

Market Talk

KMD Brands Faces Two Testing Hurdles -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Infratil's Other Assets Deserve Attention, Too -- Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Energy Roundup: Market Talk

20. mai 2026, 22:57 UTC

Market Talk

Global Equities Roundup: Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Australia Shares Set to Rise, Continue Whipsaw Week -- Market Talk

20. mai 2026, 22:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20. mai 2026, 22:27 UTC

Market Talk

SpaceX Says It Has Largest Addressable Market in 'Human History' -- Market Talk

20. mai 2026, 22:14 UTC

Market Talk

Moody's Downgrades Mexico's Sovereign Rating -- Market Talk

20. mai 2026, 22:10 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 3rd Update

20. mai 2026, 22:00 UTC

Tulu

Intuit Stock Falls on Earnings -- and the Company Plans to Cut 17% of Its Workforce -- Barrons.com

20. mai 2026, 21:38 UTC

Tulu
Omandamised, ülevõtmised, äriostud

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- 2nd Update

20. mai 2026, 21:27 UTC

Tulu

Nvidia Rides Blistering Chip Sales to Another Record Quarter -- Update

20. mai 2026, 21:20 UTC

Tulu

Nvidia CFO: Edge Computing Demand Fell Modestly Due to Higher Memory Prices

20. mai 2026, 21:19 UTC

Tulu

Nvidia Still Uncertain Whether Shipping to China Will Be Allowed, CFO Says

20. mai 2026, 21:18 UTC

Tulu

Nvidia on Track to Start Production Shipments of Vera Rubin in Second Half of This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia Projects $20B in CPU Revenue This Year, CFO Says

20. mai 2026, 21:17 UTC

Tulu

Nvidia CFO: Every Major Hyperscaler Engaged in Deploying Vera CPU

20. mai 2026, 21:17 UTC

Tulu

Nvidia's Vera CPU Opens New $200B Market, CFO Says

20. mai 2026, 21:16 UTC

Tulu

SpaceX IPO Filing Finally Comes. Mars, Musk, and More Big Things to Watch. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

11.15% tõus

12 kuu keskmine prognoos

Keskmine 103.25 USD  11.15%

Kõrge 115 USD

Madal 90 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

7

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

79.24 / 103.64Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Weak Bullish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

150 / 345 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.
help-icon Live chat